CD274 and head and neck squamous cell carcinoma: CheckMate 141 was a phase 3 trial that enrolled 361 patients with R/M SCCHN, of any tumor PD-L1 expression status, who had disease progression within 6 months after platinum-based CT (Table 4) (44).